13th Annual Palm Beach Cancer Symposium

AGENDA

Friday – March 30, 2012
7.30 AM		Registration & Breakfast
8.30 AM		Welcome and Introduction Mohammad Jahanzeb, MD
Session I: Lung Cancer—Jorge Gomez, MD
8.35 AM		Practical considerations for personalized treatment of NSCLC Ronald Natale, MD
9.00 AM		Advances in targeted therapy for lung cancer Chandra Belani, MD
9.25 AM		Surgical approaches to early-stage NSCLC Dao Nguyen, MD
9.50 AM		Clinical Case—Individualized treatment strategies for advanced NSCLC Ronald Natale, MD
10.15 AM		Debate—Maintenance therapy should be continued until progressive disease Yes: Ronald Natale, MD No: Chandra Belani, MD
10.35 AM		Expert Panel Question and Answer Session
10.55 AM		BREAK
Session II: Melanoma Mini-Session—Local Chair: Jose Lutzky, MD
11.15 AM		Advances in targeted therapy for melanoma Asim Amin, MD, PhD
11.40 AM		Clinical Case—Metastatic melanoma Asim Amin, MD, PhD
12.05 PM		Expert Panel Question and Answer Session
12.20 PM		LUNCH
Session III: Gastrointestinal (GI) Cancer—Local Chair: Caio Max Rocha Lima, MD
1.20 PM		Advances in targeted therapy for colorectal cancer Ramesh Ramanathan, MD
1.45 PM		Clinical Case—Metastatic colorectal cancer Tanios Bekaii-Saab, MD
2.10 PM		Clinical Case—HER2-positive metastatic gastric cancer Ramesh Ramanathan, MD
2.35 PM		Novel approaches to hepatocellular carcinoma Tanios Bekaii-Saab, MD
3.00 PM		Expert Panel Question and Answer
3.15 PM		Adjourn
Saturday – March 31, 2012
7.00 AM		Registration & Breakfast
8.00 AM		Welcome and Introduction Mohammad Jahanzeb, MD
Session IV: Breast Cancer—Local Chair: Orlando Silva, MD, JD
8.05 AM		Practical approaches to personalized therapy: Genomic profiling and beyond Marc Lippman, MD
8.30 AM		Advances in targeted therapy for breast cancer Stefan Glück, MD, PhD
8.55 AM		Novel approaches to breast cancer–related bone disease Christy Russell, MD
9.20 AM		Clinical Case—Discordant biopsy after progressive disease Stefan Glück, MD, PhD
9.45 AM		Debate—Can dual blockade replace chemotherapy for HER2-positive breast cancer? Yes: Stefan Glück, MD, PhD No: Christy Russell, MD
10.05 AM		Expert Panel Question and Answer
10.25 AM		BREAK
Session V: Ovarian Cancer Mini-Session—Local Chair: Reshma Mahtani, DO
10.45 AM		Advances in targeted therapy for ovarian cancer Joseph Lucci, MD
11.10 AM		Clinical Case—Platinum-sensitive ovarian cancer Joseph Lucci, MD
11.35 AM		Expert Panel Question and Answer Session
11.50 AM		Luncheon Seminar: The evolution of therapy in the management of CML This is an independent educational activity; nursing CE will not be provided.
Session VI: Prostate Cancer—Bruce Kava, MD
1.35 PM		Harnessing the immune system in the management of prostate cancer Philip Kantoff, MD
2.00 PM		Novel approaches to prostate cancer–related bone disease Michael Carducci, MD
2.25 PM		Clinical Case—Sequencing therapy for advanced prostate cancer Philip Kantoff, MD
2.50 PM		Debate—Should chemotherapy remain the standard first-line treatment of castrate-resistant prostate cancer? Yes: Michael Carducci, MD No: Philip Kantoff, MD
3.10 PM		Expert Panel Question and Answer
3.25 PM		Adjourn

CHAIRMAN

Mohammad Jahanzeb, MD
Sylvester Comprehensive Cancer Center
University of Miami
Deerfield Beach, Florida

FACULTY

Asim Amin, MD, PhD
Levine Cancer Institute
Charlotte, North Carolina

Tanios Bekaii-Saab, MD
Ohio State University
James Cancer Center
Columbus, Ohio

Chandra Belani, MD
Penn State
Milton S. Hershey Medical Center
Hershey, Pennsylvania

Michael Carducci, MD
Johns Hopkins Medical Hospital
Baltimore, Maryland

Jorge Gomez, MD
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida

Stefan Glück, MD, PhD

Sylvester Comprehensive Cancer Center

University of Miami

Miami, Florida

Philip Kantoff, MD

Dana-Farber Cancer Institute

Boston, Massachusetts

Bruce Kava, MD

Sylvester Comprehensive Cancer Center

University of Miami

Deerfield Beach, Florida

Marc Lippman, MD

Sylvester Comprehensive Cancer Center

University of Miami

Miami, Florida

Joseph Lucci, MD
Sylvester Comprehensive Cancer Center
University of Miami
Deerfield Beach, Florida

Jose Lutzky, MD
Aptium Oncology
Miami, Florida

Reshma Mahtani, DO

Sylvester Comprehensive Cancer Center

University of Miami

Deerfield Beach, Florida

Ronald Natale, MD
Cedars-Sinai Medical Center
Los Angeles, California

Dao Nguyen, MD

Sylvester Comprehensive Cancer Center

University of Miami

Miami, Florida

Ramesh Ramanathan, MD

Virginia G. Piper Cancer Center
Scottsdale Health Care

Scottsdale, Arizona

Caio Max Rocha Lima, MD

Sylvester Comprehensive Cancer Center

University of Miami

Miami, Florida

Christy Russell, MD
Keck University School of Medicine
University of Southern California

Los Angeles, California

Orlando E. Silva, MD, JD

Sylvester Comprehensive Cancer Center

University of Miami

Miami, Florida

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Discuss challenging issues and strategies for improving the management of patients with solid tumors, including melanoma, lung, gastrointestinal, breast, ovarian, and prostate cancer
Describe strategies for the integration of novel agents in the management of patients with these solid tumors with attention to clinical and molecular determinants, disease stage, comorbidities, tolerability, and other criteria for therapy selection
Integrate multimodality treatment strategies, including immunotherapy, surgery, chemotherapy, and targeted therapy, into the management of patients with solid tumors

REGISTRATION INFORMATION

The registration fee includes all activity materials, continental breakfast, lunch, and refreshment breaks.

Physicians

Preregistration: $100.00
Onsite registration: $150.00

Midlevel

Preregistration: $75.00*

Onsite registration: $125.00*

Nurses

Preregistration: $40.00*
Onsite registration: $60.00*

*Supporting documentation of eligibility may be required.

Residents/Fellows
Residents and fellows are eligible for complimentary registration. Please contact brittany.belote@oncoservices.com for more information.

ONS Members

ONS members are eligible for discounted registration rates. Please email brittany.belote@oncoservices.com with the name of your ONS chapter for more information.

Preregistration will close Tuesday, March 27, 2012. After preregistration closes, the price will increase to the onsite rate. *Attendees may still register onsite the morning of the meeting.

The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

The registration fee includes all activity materials, breakfast and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.

DISCLOSURES

Disclosure of Conflicts of Interest

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure of Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Venue & Accommodations

Westin Diplomat
3555 South Ocean Drive
Hollywood, Florida 33019
United States
Tel:(954) 602-6000
www.diplomatresort.com

Hotel reservations can be made directly with the Westin Diplomat by calling 1 (888) 627-9057. Please advise that you are with the 13th Annual Palm Beach Cancer Symposium. The conference room rate is $309/night plus applicable taxes, currently at 11%. All reservations must be confirmed with a major credit card. Reservations must be made by February 28, 2012. After February 28, 2012, rooms will be provided on a space-available basis at the standard rate.

Discounted daily parking rates:

$12 for self parking
$15 for valet

TARGET AUDIENCE
This educational activity is designed for oncologists and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with solid tumors.

CONTINUING EDUCATION

Physicians
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this live educational activity for a maximum of 10.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nursing

Nursing continuing education credits for 10.0 contact hours have been approved under Florida Provider No. 50-2900, UM Sylvester Cancer Center Nursing Education Department. A certificate of completion will be awarded at the completion of the course.

SPONSORSHIP
This activity is sponsored by prIME Oncology.

SUPPORT
Support for this educational activity is provided by:

AGENDA

LEARNING OBJECTIVES

REGISTRATION INFORMATION

DISCLOSURES

Venue & Accommodations

TARGET AUDIENCE

CONTINUING EDUCATION

SPONSORSHIP

SUPPORT